Hyperion Therapeutics (HPTX) Files $57.5M IPO

Hyperion Therapeutics (Nasdaq: HPTX) filed a registration with the U.S. Securities and Exchange Commission for an Initial Public Offering of its Common Stock. The proposed maximum offering price is $57.5 million. Hyperion plans to list on the Nasdaq Global Market under the ticker "HPTX."

The offering is being made through Leerink Swann, Cowen and Company, and Needham & Company.

Hyperion is a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat disorders in the areas of orphan diseases and hepatology.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Coherent (COHR) PT Raised to $420 at Needham
• Yxt.com Group prices $1.5M registered direct offering at $3 per ADS
• Mesoblast completes patient treatment in phase 3 back pain trial